scorecardresearch

Serum Institute starts production of Novavax's COVID-19 vaccine Covovax

Novavax's COVID-19 vaccine candidate demonstrated 100 per cent protection against moderate and severe disease and 90.4 per cent efficacy overall in phase-III trials.

Poonawalla took to Twitter to express his excitement on the beginning of production of the vaccine. Poonawalla took to Twitter to express his excitement on the beginning of production of the vaccine.

Vaccine manufacturer Serum Institute of India (SII) on Friday said it has started the production of first batch of Novavax's COVID-19 vaccine Covovax at its plant in Pune.

Earlier this month, Novavax Inc said its vaccine candidate 'NVX-CoV2373' demonstrated 100 per cent protection against moderate and severe disease, 90.4 per cent efficacy overall, and met the primary endpoint in phase-III trials.

In a tweet, SII said it has reached a new milestone by beginning the production of Covovax.

Also read: 'Gross violation': Twitter blocks, then unblocks Ravi Shankar Prasad's account

SII CEO Adar Poonawalla also took to Twitter to express his excitement on the beginning of production of the vaccine. "The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing," he said.

In September 2020, Novavax had announced COVID-19 vaccine manufacturing agreement with SII, increasing Novavax's global production capacity of NVX-CoV2373 to over 2 billion doses annually.

Announcing the trial results, Novavax had said that on getting regulatory approvals, the company will be on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021.

The company has committed to supplying 110 million doses to the US over the next year and a total of 1.1 billion doses to developing countries.

Also read: FY22 GDP may see upward revision if all adults get vaccinated: Ind-Ra